Impact Journals, a leading publisher renowned for its commitment to advancing oncology and biomedical sciences, has officially declared its role as an exhibitor at the forthcoming American Association for Cancer Research (AACR) Annual Meeting 2026. This premier event, scheduled from April 17 to April 22, 2026, will convene at the San Diego Convention Center, hosting an unparalleled gathering of global cancer researchers, clinicians, and thought leaders dedicated to the pursuit of scientific breakthroughs in cancer research.

At the heart of Impact Journals’ mission lies a profound dedication to amplifying research impact through rigorous, insightful peer review processes. By transcending traditional disciplinary boundaries, the publisher fosters an integrative scientific dialogue that links multiple specialties within oncology and biomedical science fields. This approach stimulates innovation by nurturing cross-disciplinary collaboration that bridges foundational laboratory discoveries with clinical applications to enhance patient outcomes.

Impact Journals prides itself on upholding the highest ethical standards and an unwavering commitment to scientific integrity. Leveraging state-of-the-art digital technologies and sophisticated editorial tools, they have engineered a comprehensive scientific integrity framework designed to detect and prevent research misconduct. The continual adaptation of novel technological solutions ensures their processes remain robust against emerging challenges in academic publishing, reinforcing trust in the scientific record.

The AACR Annual Meeting remains a cornerstone event for the international cancer research community, attracting thousands of participants representing diverse roles from laboratory scientists and clinical investigators to healthcare providers and patient advocates. This multidisciplinary congress elucidates cutting-edge developments spanning the entire spectrum of cancer research—from population-level epidemiology and prevention strategies to molecular biology, translational medicine, and clinical trials, as well as survivorship and advocacy initiatives.

Visitors to Impact Journals’ Booth 3641 will have the unique opportunity to engage directly with the editorial team, explore a curated selection of their most impactful recent scientific publications, and initiate meaningful collaborations. This interaction provides a fertile ground for scientific exchange, allowing attendees to discuss emerging trends in oncology research, publishing innovations, and partnership prospects that align with the translational objectives of the broader cancer research ecosystem.

Integral to Impact Journals’ offerings are its flagship peer-reviewed publications, including Aging-US, Oncotarget, Oncoscience, and Genes & Cancer. These journals collectively showcase a diverse portfolio of research encompassing molecular aging, oncogenic pathways, cancer genetics, and translational oncology, emphasizing open access dissemination to maximize knowledge accessibility and scientific dissemination globally.

The overarching goal of Impact Journals is to serve as a catalyst in the translation of comprehensive research findings into clinical and public health advancements. By fostering a seamless integration between basic biomedical research and clinical science, they support the acceleration of novel therapeutic targets, diagnostic tools, and preventative measures essential for improving oncology patient care worldwide.

Increasingly, Impact Journals utilizes transformative digital innovations such as AI-driven manuscript screening, blockchain-based peer review transparency, and advanced data visualization platforms. These tools enhance editorial efficiency, bolster reproducibility, and promote transparency in research communication, positioning Impact Journals at the vanguard of the digital academic publishing revolution.

The AACR Annual Meeting’s multi-faceted program accentuates how integrative cancer science, epidemiological insights, and innovative clinical interventions converge to shape contemporary oncology practice and future research trajectories. The presence of Impact Journals at this convocation underscores their strategic alignment with these interdisciplinary and translational imperatives.

Media representatives, researchers, and clinicians with an interest in oncology and biomedical publishing are encouraged to visit Impact Journals during the conference to gain firsthand insights into the publisher’s editorial initiatives, integrity standards, and emerging digital strategies aimed at transforming the scholarly publishing landscape.

The AACR Annual Meeting 2026 represents not only a forum for exchanging pioneering research advancements but also serves as a vibrant networking venue fostering partnerships conducive to accelerating scientific progress against cancer. Impact Journals’ engagement here exemplifies their commitment to being an active participant and facilitator in this global scientific enterprise.

For more detailed information about Impact Journals and their contributions to cancer research publishing, interested parties are invited to explore their platforms or contact their media representatives directly. This engagement will provide enhanced visibility into how the publisher is innovating within the scholarly ecosystem to elevate oncology research dissemination and impact.

Subject of Research: Cancer research, Oncology, Biomedical science publishing
Article Title: Impact Journals to Showcase Scientific Integrity and Innovation at AACR Annual Meeting 2026
News Publication Date: March 16, 2025
Web References:
– https://www.impactjournals.com/
– https://www.aacr.org/meeting/aacr-annual-meeting-2026/
Image Credits: © 2025 Rapamycin Press LLC dba Impact Journals
Keywords: Cancer research, Scientific publishing, Oncology, Academic journals, Peer review, Scientific integrity, Digital publishing, Open access, Translational medicine, Biomedical science

The i-motif structure represents a remarkable departure from the well-known Watson-Crick base pairing paradigm. Instead of the familiar adenine-thymine and cytosine-guanine pairs that stabilize the double helix, the i-motif is composed of cytosine-rich sequences that fold back on themselves, forming intercalated cytosine–cytosine base pairs. This folding produces a compact, knot-like secondary structure involving a single DNA strand, challenging the traditional view of DNA as simply a double helix. Previously dismissed as an in vitro curiosity too unstable to survive in vivo conditions, the Umeå research team has now definitively demonstrated that i-motif formations do arise within living cells, albeit fleetingly and precisely timed.

Using cutting-edge biochemical assays combined with computational modeling and sophisticated cell biology techniques, the researchers pinpointed the temporal emergence of i-DNA at a critical juncture in the cell cycle: just before the DNA replication process initiates. This narrow window suggests that i-motif structures function as regulatory checkpoints rather than static entities, forming and resolving in sync with cellular molecular machinery. The transient nature of i-DNA underscores its potential role as a selective regulator, tethering genetic expression to cellular context and timing.

Central to this regulatory mechanism is the protein PCBP1, which the study identifies as a pivotal factor in managing the formation and dissolution of the i-motif structures. PCBP1 operates by selectively unwinding the i-motif DNA at the right moment, ensuring that DNA replication proceeds unimpeded. Failure of this protein to effectively resolve i-DNA structures can result in replication fork stalling, a phenomenon linked to heightened genomic instability. Indeed, prolonged persistence of unresolved i-motifs increases the likelihood of DNA breaks, a hallmark associated with oncogenic transformation and tumor progression.

The heterogeneity of i-motif stability adds a layer of complexity to their biological function. Varying cytosine content within these structures influences their resistance to unfolding by PCBP1. Highly stable i-motifs, reinforced by additional cytosine base pairs or hybrid formations, present formidable barriers to normal DNA replication. Such stability gradients might serve as intrinsic molecular timers or switches, modulating gene expression dynamics across different chromosomal regions. Particularly notable is the enrichment of i-motif DNAs within regulatory domains of oncogenes, hinting at a direct mechanistic link between i-DNA dynamics and cancer pathophysiology.

The implications of this discovery extend far beyond molecular curiosity. Cancer cells, often subjected to excessive replication stress owing to their rapid proliferative demands, operate perilously close to the limits of DNA replication fidelity. The presence of stable i-motif structures in these cells could represent a fragility point—an “Achilles’ heel” vulnerable to therapeutic intervention. By encapsulating the molecular interplay between i-DNA and PCBP1, this study opens new avenues for drug development aimed at selectively exacerbating replication stress in malignant cells, potentially driving them towards genomic catastrophe and cell death.

At the mechanistic level, visualizing PCBP1’s stepwise unraveling of i-motif DNA elucidated previously obscure molecular choreography. The researchers employed real-time imaging and structural analyses to observe how PCBP1 recognizes, binds, and progressively destabilizes the cytosine-cytosine base pairing, facilitating the transition from a folded knot to an open, replication-competent conformation. These insights contribute to a nuanced understanding of how protein-DNA interactions govern genome stability and underscore the precision required in cellular regulation.

The transient life span of i-motif DNA within cells provides a striking example of molecular ephemerality fulfilling vital biological functions. Much like fleeting “peek-a-boo” appearances, as described by the study’s first author Pallabi Sengupta, these structures exemplify nature’s use of temporal and spatial control to regulate complex processes. The synchronization of i-DNA formation with cell cycle progression points to an evolutionary adaptation, integrating DNA structural dynamics within broader regulatory networks that oversee cellular proliferation and genome maintenance.

Furthermore, the collaborative nature of the research, involving expertise from both Umeå University and the CNRS in France, highlights the importance of interdisciplinary efforts in unraveling the complexities of DNA architecture. Combining biochemical, computational, and cellular biology approaches allowed the team to overcome longstanding technical challenges and validate the biological relevance of i-motif structures within living systems, dispelling doubts that previously relegated i-DNA to the realm of experimental artifact.

Taken together, these findings represent a paradigm shift in our understanding of DNA biology. The recognition of i-motif DNA as a functional, regulated entity within cells expands the landscape of genetic regulation and offers promising new targets for cancer therapy. By exploiting the delicate balance between formation and resolution of these knot-like DNA structures, therapeutic strategies could be devised to selectively compromise the proliferative capacity of tumor cells without damaging normal tissue.

As research continues to elucidate the diverse roles of alternative DNA structures, the i-motif provides a compelling example of how DNA’s versatility extends beyond the double helix to orchestrate critical cellular events. This study unlocks possibilities for future investigations into how such structures interact with the full complement of nuclear proteins and the epigenetic landscape, potentially influencing gene expression, chromatin organization, and cellular response to stress.

The journey from perceiving the i-motif as a scientific curiosity to recognizing its integral place within molecular biology showcases the dynamic and evolving nature of genetic research. With the advances presented by the Umeå team, the foundation is laid for a new era of molecular medicine, leveraging the unique vulnerabilities of DNA secondary structures for innovative cancer treatments that could transform patient outcomes worldwide.

Subject of Research: Cells

Article Title: Mechanistic insights into PCBP1-driven unfolding of selected i-motif DNA at G1/S checkpoint. Nature Communications

News Publication Date: 2-Feb-2026

Web References: 10.1038/s41467-026-68822-5

Image Credits: Mattias Pettersson

Keywords: i-motif DNA, PCBP1, DNA replication, cytosine base pairs, DNA secondary structure, genome stability, cancer biology, replication stress, DNA-protein interaction, gene regulation, DNA folding, oncogene regulation

Breast cancer remains one of the most prevalent and deadly forms of cancer worldwide. Despite significant advancements in treatment and management, many patients still face recurrence and metastasis, leading to poor prognosis. A critical area of investigation has centered around the metabolic adaptations that tumors undergo to thrive in the hostile environment of the human body. The loss of isozyme diversity is an underappreciated factor that may contribute to these metabolic shifts.

Isopytes, or isozymes, are different enzymes that catalyze the same reaction but are regulated differently. These variations can result from genetic or environmental factors and play a crucial role in cellular metabolism. In normal tissues, isozyme diversity allows for metabolic flexibility, enabling cells to adapt to changing conditions. However, the research team discovered that this diversity is often compromised in breast cancer, leading to stark metabolic vulnerabilities.

Ding et al. conducted a comprehensive analysis of tumor samples from breast cancer patients, employing state-of-the-art techniques including metabolomics and transcriptomics. Their findings revealed that loss of specific isozymes not only limits the metabolic pathways available to tumors but also increases their susceptibility to targeted therapies. This discovery has profound implications for developing treatment strategies that exploit these vulnerabilities.

One of the most striking observations was that tumors exhibiting reduced isozyme diversity displayed altered utilization of nutrients. Specifically, cancer cells exhibited a dependency on specific amino acids and fatty acids, which are critical for tumor growth and proliferation. By targeting these metabolic pathways, clinicians may have the opportunity to starve these tumors and inhibit their growth effectively.

The study also highlights the potential for developing a metabolic biomarker based on isozyme expression profiles. Such biomarkers could predict a patient’s response to therapy and guide personalized treatment approaches. This innovative strategy could enhance the efficacy of existing treatment modalities and reduce the incidence of treatment resistance, which is a significant hurdle in cancer therapy.

Moreover, the research provides insights into the tumor microenvironment. The interaction between cancer cells and their surrounding stroma plays a pivotal role in modulating isozyme expression. This relationship can create a feedback loop that exacerbates metabolic vulnerabilities. Understanding this interplay could lead to multi-faceted therapeutic strategies that target both the tumor and its microenvironment.

The results of this study also raise critical questions about the role of metabolic inhibitors in cancer treatment. While existing drugs primarily focus on disrupting cancer cell proliferation, targeting the metabolic dependencies associated with isozyme loss may provide a complementary strategy. Researchers suggest that combining traditional therapies with metabolic inhibitors could potentiate antitumor effects and improve patient outcomes.

In light of these findings, there is an urgent need for clinical trials to investigate isozyme-targeted therapies. The promising results from Ding and colleagues underscore the importance of understanding the biochemical landscape of cancer cells. It also emphasizes the necessity of collaboration between molecular biologists, oncologists, and pharmacologists to harness these insights into actionable clinical applications.

Furthermore, the implications of this research extend beyond breast cancer alone. The metabolic vulnerabilities associated with isozyme loss may be a recurring theme across various cancer types. Similar mechanisms could be responsible for tumor survival in other malignancies, suggesting a larger paradigm shift in cancer treatment based on metabolic vulnerabilities.

As this field evolves, it is crucial for researchers to prioritize integrative approaches that combine genomic data, metabolic profiling, and clinical outcomes. By doing so, scientists can foster a holistic understanding of cancer metabolism and the role it plays in therapeutic resistance. The culmination of these efforts may usher in a new era of cancer treatment that moves away from conventional methodologies toward precision-targeted strategies.

The potential to identify and exploit collateral vulnerabilities in cancer metabolism offers hope for patients facing the grim outlook of advanced disease. By targeting the very mechanisms that tumors use to survive and proliferate, the medical community could transform treatment paradigms and improve survival rates. Ongoing research will be essential to validate these findings and translate them into clinical practice.

In conclusion, the study by Ding et al. serves as a pivotal contribution to the understanding of breast cancer metabolism. By revealing the impact of isozyme diversity loss on tumor vulnerabilities, this research sets the stage for innovative approaches to treatment that could significantly enhance patient outcomes. The future lies in our ability to harness this knowledge and develop therapies that not only target the cancer directly but also its metabolic underpinnings.

Subject of Research: Loss of isozyme diversity in breast cancer and its impact on metabolic vulnerabilities.

Article Title: Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.

Article References:

Ding, R., Yu, TJ., Jiang, YZ. et al. Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.
Genome Med 18, 7 (2026). https://doi.org/10.1186/s13073-025-01573-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13073-025-01573-y

Keywords: Isozyme diversity, breast cancer, metabolic vulnerability, therapeutic strategies, cancer metabolism, targeted therapies, biomarker development.

At the heart of this research lies the LKB1/STK11 gene, a well-known tumor suppressor that plays a pivotal role in regulating cellular metabolism and growth. The loss of LKB1 has been shown to be linked with various types of cancers, including lung cancer and gastrointestinal tumors. Understanding the molecular consequences of LKB1 loss has become increasingly critical, especially given the prevalence of mutations in this gene among different cancer types. By delving into the metabolic adaptations that occur when LKB1 is lost, the researchers have uncovered an intriguing interplay between leptin, a hormone known for its regulatory role in energy balance and appetite control, and mitochondrial function.

Leptin, often referred to as the “satiety hormone,” is produced by adipose tissue and communicates with the hypothalamus to regulate hunger and energy expenditure. However, its role extends beyond appetite regulation; it is increasingly recognized as an important player in cancer biology. The study highlights how leptin can influence cancer cell metabolism, particularly under conditions where LKB1 is compromised. By demonstrating that leptin contributes to a heightened sensitivity to mitochondrial uncouplers in LKB1-deficient cancer cells, the research underscores a potential vulnerability that could be exploited for therapeutic purposes.

Mitochondrial uncouplers are compounds that disrupt the typical coupling of electron transport and ATP synthesis in the mitochondria, leading to increased energy expenditure and the generation of reactive oxygen species. In cancer cells, where metabolic pathways often become rewired, the application of mitochondrial uncouplers prompts a unique metabolic stress that can selectively target cancerous cells. This selective sensitivity opens exciting possibilities for targeted cancer therapies, particularly for tumors characterized by the loss of LKB1.

The findings of this research have significant implications for cancer therapy, particularly in tailoring treatments to the metabolic profiles of tumors. The concept of “targeted cancer therapy” involves understanding the underlying molecular mechanisms that drive tumor growth and using this knowledge to design drugs that exploit specific vulnerabilities in cancer cells. The revelation that leptin could mediate sensitivity to mitochondrial uncouplers presents a new avenue to leverage this hormonal pathway for therapeutic interventions.

Furthermore, the study emphasizes the potential to combine mitochondrial uncouplers with other treatment modalities to enhance therapeutic efficacy. As the landscape of cancer therapy continues to evolve, the integration of metabolic targeting strategies with traditional approaches like chemotherapy and immunotherapy could lead to more effective and personalized treatment regimens. This multidimensional approach to cancer treatment aligns with the growing movement towards precision medicine, where therapies are designed based on individual tumor characteristics.

While the research presents promising avenues, it also raises important questions regarding the broader implications of targeting energy metabolism in cancer therapy. As researchers explore these metabolic vulnerabilities, understanding the potential side effects and long-term outcomes of disrupting such pathways will be crucial. The balance between therapeutic effectiveness and the preservation of normal cellular functions must be carefully managed to mitigate adverse effects that could arise from targeting energy metabolism.

In conclusion, the research led by Angelopoulou and colleagues marks a significant advancement in our understanding of the interplay between tumor suppressor loss, hormonal regulation, and mitochondrial function in cancer cells. The identification of leptin-mediated sensitivity to mitochondrial uncouplers in LKB1-deficient tumors is a noteworthy breakthrough that could reshape the strategies employed in cancer therapy. The insights gleaned from this study not only lay the groundwork for future research but also underscore the importance of dissecting metabolic pathways to identify new therapeutic targets.

As the scientific community continually strives to uncover the complexities of cancer biology, studies like this one serve as vital reminders of the potential for innovation in treatment strategies. As researchers expand upon these findings, the hope is that new, effective therapies will emerge, providing patients with improved outcomes and ultimately transforming the landscape of cancer care.

Understanding the molecular mechanisms at play in cancers driven by LKB1 deficiencies will be critical as therapeutic strategies evolve with time. The research community must galvanize around this newfound knowledge to cultivate a deeper understanding of the metabolic vulnerabilities present in diverse tumor types. With renewed focus on metabolic pathways, novel therapeutic compounds that target these specific vulnerabilities may soon follow.

In essence, the road ahead promises excitement and hope as researchers harness the molecular insights gleaned from studies like those conducted by Angelopoulou et al. The intertwining of hormonal signaling, metabolism, and tumor biology is complex yet offers fertile ground for discovery and innovation as the relentless fight against cancer continues. With further investigation and clinical translation, the research findings could lead not only to enhanced therapeutic approaches but also to a paradigm shift in how we comprehend and combat cancer on a molecular level.

As more researchers delve into the implications of LKB1 loss and associated metabolic pathways, a clearer picture will emerge, providing a robust foundation for the development of targeted therapies. Future studies will undoubtedly expand upon these findings, potentially revolutionizing the approach to treating LKB1-deficient tumors and enhancing the armamentarium in the quest for effective cancer therapies.

Subject of Research: The relationship between LKB1/STK11 loss and leptin-mediated sensitivity to mitochondrial uncouplers in cancer treatment.

Article Title: Correction: Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy.

Article References: Angelopoulou, A., Theocharous, G., Valakos, D. et al. Correction: Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy. Mol Cancer 25, 11 (2026). https://doi.org/10.1186/s12943-025-02561-x

Image Credits: AI Generated

DOI:

Keywords: LKB1, leptin, mitochondrial uncouplers, cancer therapy, tumor metabolism, targeted therapy.

The cornerstone of this innovative study is the examination of 1233 formalin-fixed, paraffin-embedded (FFPE) solid tumor samples. These samples represent a diverse array of cancers, enabling the researchers to explore the intricacies of each tumor’s gene expression profile. By leveraging whole transcriptome sequencing, which captures the complete RNA content of each sample, the research team was able to uncover a wealth of information that traditional sequencing methods often miss.

Whole transcriptome sequencing, often abbreviated as WTS, stands out due to its ability to provide a holistic view of the transcriptional landscape. This method detects not only the expressed genes but also the alternative splicing events and non-coding RNAs that play critical roles in various biological processes. Given the complexities of cancer, where gene expression can dramatically differ based on tumor type and stage, utilizing WTS offers unparalleled insights into patient-specific tumor biology.

One of the key challenges in cancer genomics is the degradation of RNA in FFPE samples, a common preservative technique used in clinical settings. The team implemented innovative protocols to optimize RNA retrieval and sequencing, ensuring that the data generated was both accurate and reliable. This meticulous approach to sample preparation highlights the importance of technical precision in genomic studies, particularly when dealing with archived specimens that have inherent degradation factors.

As the study unfolds, the implications of the findings extend beyond mere academic interest. The detailed gene expression analyses allow for improved classification of tumor subtypes and may enhance prognostic predictions. By correlating specific gene expression profiles with clinical outcomes, the researchers have paved the way for a more personalized approach to cancer therapy. This stratification could lead to tailored treatment plans that align with the unique molecular characteristics of each patient’s tumor.

Moreover, this research serves to enhance our understanding of the tumor microenvironment. The interplay between cancer cells and their surrounding stromal and immune cells plays a crucial role in tumor progression and response to therapy. With WTS, the researchers can elucidate the dynamics of these cellular interactions at a molecular level, potentially identifying new therapeutic targets and biomarkers. Such discoveries are vital in the ongoing battle against cancer, where understanding the tumor ecosystem can be as important as targeting the cancer cells themselves.

In addition to its immediate clinical applications, the study’s findings contribute to the larger narrative of cancer research. They underscore a shift towards integrating transcriptomic data with other forms of genomic and proteomic information, fostering a more comprehensive understanding of cancer pathology. This multidimensional approach could herald a new era of cancer research, where therapies are not only aimed at eradicating tumors but are also informed by a deeper understanding of individual tumor biology.

The reception of the study’s findings is likely to resonate through the scientific community, inspiring further research that builds on these insights. The ability to analyze such a large cohort of solid tumor samples with advanced sequencing technology may catalyze new collaborations and studies, ultimately enriching the field of oncology and providing new hope for patients.

Furthermore, the implications of whole transcriptome sequencing extend beyond diagnostics; they also hold potential in the realm of therapeutic development. By understanding the genetic and epigenetic drivers of tumorigenesis, pharmaceutical companies may be able to design novel therapies that specifically target the unique vulnerabilities of different tumors. This represents a significant shift from the traditional one-size-fits-all approach to a more nuanced strategy in cancer treatment.

Ethical considerations surrounding genomic data will also be paramount in the aftermath of this research. As genomic sequencing becomes more embedded in clinical practice, issues related to patient consent, data privacy, and the implications of genetic information must be addressed. The study offers an opportunity to engage in these discussions, shaping the policies that govern genomic medicine in the future.

The overarching message of this research is one of optimism and potential. While the path to a complete understanding of cancer is fraught with challenges, the advancements brought forth by the integration of whole transcriptome sequencing into diagnostic pathways demonstrate considerable promise. The ability to obtain comprehensive transcriptomic data from FFPE samples marks a crucial leap forward in realizing the goal of precise, individualized cancer care.

As the implications of this study unfold in clinical settings, the anticipation surrounding its practical applications will likely build. Clinicians and researchers alike are eagerly awaiting further insights that can enhance current modalities of cancer treatment. The convergence of novel technologies and rigorous scientific inquiry stands poised to transform our approach to cancer, illustrating the enduring power of research in unlocking the mysteries of this complex disease.

Thus, the publication of this research does not merely contribute to the literature; it catalyzes a movement towards innovation and discovery in cancer diagnostics and therapeutics. Through a combination of advanced technologies, meticulous methodologies, and a keen focus on patient outcomes, the research team has set the stage for a brighter future in oncology.

Given the urgency of tackling global cancer burdens, this study represents a timely and essential contribution to the fight against cancer. It is a vivid reminder of the potential that lies in genomic medicine to redefine how we understand, diagnose, and ultimately treat one of humanity’s most challenging health issues.

In conclusion, as we stand on the brink of new frontiers in cancer research, the insights gleaned from this study amplify a growing recognition of the power of whole transcriptome sequencing. The landscape of cancer diagnostics and treatment is evolving, and this work serves as a crucial landmark on that journey. It exemplifies the intersection of science and clinical practice, calling for an era where personalized medicine becomes the standard, ultimately leading to improved outcomes for cancer patients worldwide.

Subject of Research: Diagnostic whole transcriptome sequencing in solid tumors

Article Title: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

Article References:

Ball, M., Beck, S., Wlochowitz, D. et al. Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples.
Br J Cancer (2026). https://doi.org/10.1038/s41416-025-03307-8

Image Credits: AI Generated

DOI: 10.1038/s41416-025-03307-8

Keywords: whole transcriptome sequencing, cancer diagnostics, personalized medicine, FFPE samples, gene expression analysis.

PRMT6, an enzyme known for its post-translational modification of proteins, catalyzes the methylation of arginine residues on target proteins. This biochemical modification can influence various cellular processes, including gene expression, cell signaling, and response to stress. In the context of glioblastoma, the study proposes that hypoxia-induced expression of PRMT6 contributes significantly to the cancer’s ability to withstand the cytotoxic effects of TMZ, a challenge that has stymied treatment efforts for years.

The researchers employed a combination of in vitro and in vivo approaches to investigate the relationship between hypoxia, PRMT6 expression, and TMZ resistance. By subjecting glioblastoma cell lines to hypoxic conditions, the team observed a marked increase in PRMT6 levels. This correlation prompted further investigation into the downstream effects of PRMT6 upregulation, particularly its influence on the Golgi Nucleotide-binding protein 1 (G3BP1), a key player in mRNA metabolism and cellular stress responses.

Inhibition studies revealed that silencing PRMT6 expression using small interfering RNA markedly decreased the proliferation rate of glioblastoma cells in hypoxic conditions, thereby implicating PRMT6 as a critical promoter of cellular viability under stress. The findings suggest that glioblastoma cells exploit PRMT6 upregulation as a mechanism to counteract the apoptosis typically induced by temozolomide treatment. The prognostic implications of this discovery are profound; targeting PRMT6 may sensitize these cells to TMZ, potentially improving clinical outcomes for patients suffering from GBM.

Moreover, the study emphasizes the significant interplay between tumor microenvironment factors such as hypoxia and the epigenetic landscape of cancer cells. As PRMT6 modifies target proteins, it may alter the transcriptional programs involved in drug resistance and cell survival. The authors argue that understanding these regulatory networks could pave the way for new therapeutic strategies aiming to re-sensitize glioblastoma to existing chemotherapeutics, including TMZ.

Addressing the biochemical mechanisms underlying chemoresistance is critical, as GBM remains notoriously difficult to treat. The median overall survival of patients diagnosed with GBM has remained stagnant for decades, indicating an urgent need for innovative treatment modalities. By targeting the PRMT6-G3BP1 axis, researchers could potentially enhance the efficacy of current therapies and clear the barriers to successful treatment of this aggressive malignancy.

Furthermore, the study highlights the importance of considering the tumor’s microenvironment as a dynamic entity that influences cancer progression and response to therapy. Hypoxia, a common feature of solid tumors, is known to induce metabolic adaptations that allow cancer cells to thrive in low-oxygen conditions. As the findings of Chen et al. demonstrate, these adaptations can also lead to significant alterations in drug response, especially in the face of standard chemotherapeutic protocols.

In clinical practice, the implications of this research extend beyond just understanding chemoresistance mechanisms. If the PRMT6 pathway can be effectively targeted, it may open doors to a combinatorial therapeutic approach that utilizes both hypoxia-modulating agents and traditional chemotherapeutics. By disrupting not only the metabolic footprint of glioblastoma but also its resistance mechanisms, there exists a potential to significantly improve patient outcomes.

Moreover, the study underscores a paradigm shift that may influence future GBM research. The identification of PRMT6 as a pivotal factor in hypoxia-related chemoresistance invites further exploration into its role across various cancer types. The quest to delineate the molecular players involved in therapy resistance could lead to the discovery of biomarkers that predict treatment response, ushering in an era of personalized medicine tailored to the unique molecular profiles of patients’ tumors.

In conclusion, the recent findings by Chen and colleagues underscore the significance of PRMT6 in promoting temozolomide chemoresistance in glioblastoma under hypoxic conditions. This intricate interplay between hypoxia and epigenetic regulation presents an exciting opportunity for future therapeutic strategies aimed at overcoming the challenges posed by this challenging malignancy. As the landscape of cancer treatment evolves, integrating molecular research with clinical applications could herald a new chapter in the management of glioblastoma, ultimately improving survival rates and quality of life for patients worldwide.

The narrative crafted by these insightful findings beckons a renewed focus on the cellular and molecular dynamics of glioblastoma. With ongoing research into the mechanistic pathways involved in chemoresistance, the potential for innovative treatment options appears promising. Researchers and clinicians alike must consider the implications of hypoxia and its role in shaping tumor behavior, as well as the significance of PRMT6 in modulating the therapeutic landscape of glioblastoma treatment.

As discussions about targeted therapies and personalized medicine continue to gain momentum, the study serves as a reminder that understanding the biological underpinnings of cancer can lead to actionable insights that directly impact patient care. It is essential to keep exploring the depths of tumor biology to uncover vulnerabilities that can be exploited in the pursuit of more effective and enduring treatments for glioblastoma and beyond.

By embracing a multidisciplinary approach that incorporates molecular biology, pharmacology, and clinical expertise, the quest to conquer glioblastoma becomes not just a dream but a tangible objective within reach. As researchers build upon the findings of Chen and colleagues, the hope remains that glioblastoma will no longer be synonymous with despair, but rather with resilience and breakthroughs that redefine cancer care strategies.

Subject of Research: Glioblastoma Chemoresistance Mechanisms

Article Title: Hypoxia-Induced PRMT6 Expression Promotes Temozolomide Chemoresistance in Glioblastoma via G3BP1

Article References:

Chen, S., Yu, P., Sun, Y. et al. Hypoxia-induced PRMT6 expression promotes temozolomide chemoresistance in glioblastoma via G3BP1.
J Transl Med (2026). https://doi.org/10.1186/s12967-025-07618-5

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07618-5

Keywords: glioblastoma, chemoresistance, temozolomide, PRMT6, hypoxia, G3BP1, cancer treatment, epigenetics, molecular pathways.

Breast cancer remains one of the leading health challenges, affecting millions of women worldwide. Traditional diagnostic methods often rely heavily on imaging technologies like mammography and breast ultrasounds, which can sometimes yield false positives or negatives. This reality not only introduces anxiety for patients but may also delay critical treatment decisions, contributing to adverse outcomes. As healthcare professionals strive for better methods, diffuse reflectance spectroscopy emerges as a beacon of hope, promising to refine the diagnostic landscape of breast cancer with greater accuracy.

At its core, diffuse reflectance spectroscopy leverages the interaction between light and tissue to assess the biochemical composition of the breast. When light is directed onto tissue, it is scattered and absorbed by various cellular components. By analyzing the spectrum of light that is reflected back, researchers can identify pathological changes associated with tumors. This non-invasive approach enables clinicians to obtain real-time information about tissue composition, facilitating a more informed assessment of breast health.

One of the critical advantages of diffuse reflectance spectroscopy is its ability to provide a detailed biochemical profile of breast tissue without the need for invasive procedures, such as biopsies. This characteristic not only minimizes patient discomfort but also allows for quicker diagnostic turnaround times. In clinical settings, swift decisions regarding treatment can be made, which is vital in managing aggressive forms of breast cancer where time is of the essence.

The research team utilized a sophisticated algorithm to analyze the spectral data collected through diffuse reflectance spectroscopy. By integrating machine learning techniques, they were able to enhance the sensitivity and specificity of the diagnostic process. This artificial intelligence backbone aids in distinguishing between benign and malignant tissues with remarkable accuracy, providing clinicians with a powerful tool in their diagnostic arsenal.

The implications of this advancement extend beyond mere accuracy in diagnosis. For patients, a more reliable diagnostic tool can alleviate anxiety and lead to a more personalized treatment approach. When clinicians can differentiate between types of tissue abnormalities, tailored therapies can be implemented sooner, thereby improving overall outcomes. This personalized approach not only empowers healthcare providers but also places patients at the center of their treatment plans.

Moreover, the introduction of diffuse reflectance spectroscopy aligns seamlessly with the push toward precision medicine—a paradigm shift in healthcare that advocates for individualized treatment strategies based on personal variability. The ability to analyze the molecular features of breast tissue aligns perfectly with the goals of precision medicine, aiming to optimize treatment efficacy while minimizing unnecessary interventions.

As promising as this technology is, its integration into clinical practice requires careful consideration. The research demonstrates the need for extensive clinical validation to establish standardized procedures and to train healthcare professionals in this novel diagnostic approach. Additionally, overcoming potential barriers to adoption will require collaboration among researchers, clinicians, regulatory bodies, and healthcare systems to ensure that this technology is widely accessible and can be implemented safely and effectively.

In the race against breast cancer, this innovative application of diffuse reflectance spectroscopy is not just an incremental improvement; it’s a transformative approach that signifies a pivotal moment in cancer diagnostics. As studies continue to validate its efficacy, the hope is that diffuse reflectance spectroscopy will soon be a staple in breast cancer assessment, enhancing clinician capability and improving patient outcomes significantly.

While the journey from scientific discovery to clinical implementation is fraught with challenges, the enthusiasm surrounding this advancement is palpable. Researchers and clinical practitioners alike are eager to witness how this technique can reshape the diagnostic landscape of breast cancer. With continued investment in research and a commitment to technological integration, the dream of a future where breast cancer is diagnosed accurately and non-invasively may soon be realized.

This innovative study, as reported in the Journal of Translational Medicine, not only charts a new course in the detection of breast cancer but also invigorates the broader conversation on the importance of using advanced technologies to address pressing healthcare challenges. As the medical community prepares to embrace this new frontier in cancer diagnostics, the transformation in patient care and treatment protocols is poised to be profound, underlining the critical role of technology in modern medicine.

Subject of Research: Enhanced diagnostic precision in breast cancer using diffuse reflectance spectroscopy.

Article Title: Diffuse reflectance spectroscopy for enhanced diagnostic precision in breast cancer.

Article References:

Feenstra, L., Guimaraes, M.D.S., Drukker, C.A. et al. Diffuse reflectance spectroscopy for enhanced diagnostic precision in breast cancer.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07556-2

Image Credits: AI Generated

DOI:

Keywords: Diffuse reflectance spectroscopy, breast cancer diagnostics, precision medicine, non-invasive techniques, machine learning, clinical validation.

In a groundbreaking study, researchers have unveiled a new class of anticancer agents derived from alepterolic acid, specifically designed to combat breast cancer. This innovative research led by Ma, Sun, and Zhang opens new avenues for breast cancer treatment, a disease that continues to affect millions worldwide. Their work highlights the significant potential of small molecule drugs in targeting cancer cells more selectively, minimizing adverse effects associated with conventional therapies.

The team’s focus was on the design and synthesis of a range of alepterolic acid derivatives, which cleverly incorporate indole and piperazine moieties. This strategic chemical manipulation enhances the bioactivity of these compounds, making them formidable contenders in the battle against breast cancer. The indole and piperazine additives are particularly noteworthy, as they are known to exhibit a wide range of biological activities, which could lead to more efficacious cancer treatments. By enhancing the pharmacological profile of alepterolic acid, the research addresses a pressing need for more effective chemotherapy options.

Breast cancer remains one of the leading causes of cancer-related deaths, emphasizing the urgency for novel therapeutic strategies. The research conducted by Ma et al. not only targets the cancer cells more effectively but also aims to understand the underlying mechanisms through which these newly synthesized compounds operate. By elucidating the mechanisms of action, the study creates a pathway that aids in the rational design of future anticancer agents. This systematic approach ensures that the compounds developed are optimized for both efficacy and safety.

In vitro studies revealed that certain derivatives displayed remarkable cytotoxicity against breast cancer cell lines. This highlights the potential for these compounds to induce apoptosis, a process that selectively destroys cancerous cells while leaving normal cells relatively unscathed. The specificity of these new agents offers a paradigm shift in oncology, as it addresses the critical balance between therapeutic efficacy and the preservation of healthy tissue.

To further understand the impact of the newly synthesized compounds, the research team engaged in rigorous mechanistic evaluation. Through a series of cellular and molecular assays, they identified critical pathways involved in the cytotoxic effects of these derivatives. The interplay between signaling pathways provides insights into how these innovative agents can disrupt cancer cell proliferation and survival. This aspect of the research is vital for the continued development of targeted therapies that not only inhibit tumor growth but also mitigate the chances of resistance.

Moreover, the compounds’ pharmacokinetic profiles were assessed, providing essential data on their absorption, distribution, metabolism, and excretion. Optimization of these characteristics is crucial for successful translation from bench to bedside. By prioritizing compounds with favorable pharmacokinetics, the researchers increase the likelihood of successful clinical applications, ultimately enhancing patient outcomes in breast cancer treatment.

Collaboration across disciplines was a cornerstone of the study, bringing together chemists, biologists, and pharmacologists. This interdisciplinary approach fosters innovation, allowing for the efficient synthesis and evaluation of new drug candidates. Such teamwork is vital in the fast-paced realm of drug discovery, where the convergence of skillsets can lead to groundbreaking advancements in cancer therapy.

The promising results of this research pave the way for further investigation into the safety and efficacy of these alepterolic acid derivatives in vivo. Future studies will focus on animal models, aiming to establish proof of concept before progressing to human clinical trials. This transition from laboratory research to clinical application is a monumental step that requires meticulous planning and execution to ensure patient safety and efficacy.

As we delve deeper into the molecular intricacies of cancer, the potential of small-molecule therapies like the ones developed in this study cannot be overstated. The incorporation of indole and piperazine structures not only enhances the biological activity but also provides a template for the future design of anticancer agents. The versatility of these small molecules opens new doors for the treatment of various cancer types, expanding the breadth of therapeutic options available to oncologists.

The implications of this research extend beyond breast cancer treatment. The knowledge gained from understanding the mechanism of action can be applied to other cancers, broadening the scope of impact. Researchers are optimistic that the successful development of these compounds could signify the dawn of a new generation of anticancer drugs, tailored to disrupt the unique biological landscape of different malignancies.

The dedication of the researchers involved in this study embodies the spirit of scientific inquiry and innovation. Their commitment to addressing one of the most pressing health challenges of our time reflects a determination to improve lives. With continued investment in research and development, the goal of creating more effective and targeted cancer therapies is becoming increasingly attainable.

In conclusion, the promising findings surrounding alepterolic acid derivatives represent a pivotal moment in cancer research. As scientists unlock the potential of these compounds, the hope for improved breast cancer treatments becomes more tangible. The meticulous design, synthesis, and evaluation of these novel agents stand as a testament to the power of science in the fight against cancer, igniting optimism for the future of cancer therapy.

Subject of Research: New anticancer agents derived from alepterolic acid targeting breast cancer.

Article Title: Design, synthesis, and mechanistic evaluation of alepterolic acid derivatives incorporating indole and piperazine moieties as anticancer agents targeting breast cancer.

Article References: Ma, L., Sun, Y., Zhang, B. et al. Design, synthesis, and mechanistic evaluation of alepterolic acid derivatives incorporating indole and piperazine moieties as anticancer agents targeting breast cancer. Mol Divers (2025). https://doi.org/10.1007/s11030-025-11406-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11406-0

Keywords: alepterolic acid, indole, piperazine, breast cancer, anticancer agents, drug design, cancer therapy, apoptosis, pharmacokinetics, molecular mechanisms.

Alpha-emitting radionuclides have garnered attention in recent years for their potential to selectively destroy tumor cells while sparing healthy tissues. The localized effect of alpha radiation makes it a compelling choice for therapeutic interventions targeting cancer. However, the challenge has always been about delivering these alpha emitters precisely to the tumor site without triggering systemic toxicity. This study presents a solution by employing a clever design inspired by natural chemical processes.

The Diels–Alder reaction is a well-known organic chemical reaction that forms complex cyclic structures, and the study harnesses this reaction’s robust characteristics to create a self-immolative molecular cage. Such cages act as carriers for the alpha-emitting isotopes, ensuring that they are delivered specifically to the target tumor cells. Once the molecular cage interacts with tumor-specific markers, it undergoes a transformation, releasing the alpha-emitting agent right at the site where it is most needed. This ingenious delivery mechanism promises to enhance the efficacy of alpha-emitting radionuclides significantly.

The researchers tested the dual-locked molecular cage strategy in various cancer models, demonstrating its safety and therapeutic potential. Promising results were observed, showing not only improved tumor targeting but also a reduction in off-target effects typically associated with traditional chemotherapy and radiotherapy approaches. This targeted approach reduces the collateral damage to adjacent healthy tissues, a significant breakthrough in oncological treatment that can profoundly impact patient quality of life.

In animal models, the results were astonishing. The tumors exhibited remarkable regression, and the combination of targeted alpha-emitter delivery with immunotherapy showed synergistic effects. This dual approach stimulates the immune response while simultaneously attacking the cancer cells, which could lead to more durable therapeutic outcomes. The immune system’s ability to recognize and attack residual cancer cells after initial treatment could drastically lower recurrence rates.

Moreover, the self-immolative nature of the molecular cage means that once it releases its cargo, it disassembles itself into non-toxic products that the body can easily eliminate. This feature is crucial in preventing potential long-term toxicity from the carrier itself, addressing one of the major concerns in therapeutic radiochemistry. The scientists involved in this research believe this could set a new standard for how targeted radiotherapy is conducted in clinics.

In the broader context of cancer treatment, this study highlights the increasing importance of personalized medicine. By utilizing specific tumor markers to guide the delivery of therapeutics, physicians could tailor treatment plans that are not only effective but also less taxing on patients. The implications of this research extend well beyond just alpha emitters; it opens doors for new combinations of therapies that utilize the precise targeting capabilities of advanced drug delivery systems.

Furthermore, as the cancer research community continues to pursue avenues for improving response rates, understanding the interplay between tumor biology and the immune system remains critical. This research addresses that intersection by leveraging both physical and biological mechanisms to eradicate tumors more effectively. As insights into tumor microenvironments deepen, such innovative strategies will likely become central to future oncological therapies.

In summary, the study led by Yang et al. stands as a beacon of hope within the ever-evolving landscape of cancer treatment. By merging advanced chemical strategies with novel therapeutic applications, researchers are carving pathways to more effective and less harmful cancer therapies. The ongoing research and clinical trials stemming from this work will be watched with great anticipation by both the scientific community and patients alike.

This dual-locked targeted approach exemplifies the necessity of interdisciplinary collaboration in addressing complex medical challenges. As researchers continue to build on the foundational work established in this study, the potential for enhanced survival rates and improved quality of life for cancer patients worldwide becomes increasingly promising. In a field that is often defined by its trials and tribulations, innovations such as this remind us of the incredible progress being made in the fight against cancer.

The need for effective cancer therapies has never been more urgent, and this research aligns with a broader movement towards harnessing the body’s own immune responses to combat disease. As trials move forward, the hope is that this breakthrough will lay the groundwork for future generations of cancer therapeutics, combining newly discovered agents with established treatment modalities in transformative ways.

Ultimately, this research illuminates a path forward—one that not only addresses the immediate challenges of tumor targeting but also fosters a renewed optimism in the ongoing battle against one of humanity’s most formidable adversaries: cancer.

Subject of Research: Dual-locked targeted alpha-emitter enhanced tumor immunotherapy

Article Title: Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels–Alder reaction-based self-immolative molecular cage strategy.

Article References: Yang, MD., Fang, K., Zhang, XY. et al. Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels–Alder reaction-based self-immolative molecular cage strategy. Military Med Res 12, 84 (2025). https://doi.org/10.1186/s40779-025-00673-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40779-025-00673-5

Keywords: Tumor immunotherapy, alpha-emitter, Diels-Alder reaction, molecular cage, cancer treatment, targeted therapy, immunological response, drug delivery system.

Prostate cancer remains one of the most prevalent forms of cancer among men worldwide. The challenge with treating this type of cancer lies in its heterogeneous nature and the intricate molecular pathways that contribute to its development and metastasis. In their study, the researchers explored how FOXD3-AS1 interacts with various molecular players, particularly miR-491-5p, to influence cancer cell behavior. The intricate balance that exists between these molecules reveals a potential point of intervention in cancer therapy.

The researchers employed a series of in vitro experiments to dissect the role of FOXD3-AS1 in prostate cancer. By strategically silencing the lncRNA, they observed not only a reduction in cell proliferation but also an increase in apoptosis—a process that is often dysregulated in cancer. This finding is especially significant; enhancing apoptosis in cancer cells can lead to more efficient tumor regression. The study highlights the potential of targeting such non-coding RNAs in designing new therapeutic strategies.

Moreover, the interplay between FOXD3-AS1 and miR-491-5p forms a crucial axis in driving prostate cancer progression. MicroRNAs (miRNAs) serve as critical post-transcriptional regulators in various biological processes, including cell growth, differentiation, and apoptosis. In their study, Yu and colleagues provided evidence that FOXD3-AS1 could act as a sponge for miR-491-5p, effectively sequestering it and thereby reducing its regulatory control over downstream targets like PEG10. The implications of this interaction are profound, suggesting that disrupting FOXD3-AS1 could restore the function of miR-491-5p, ultimately inhibiting tumor growth.

PEG10, a gene that has been implicated in various cancers, including prostate cancer, appears to play a significant role in promoting cell proliferation and survival. The findings from the study suggest that the depletion of FOXD3-AS1 leads to increased levels of miR-491-5p, which subsequently suppresses PEG10 expression. This mechanism highlights a potential therapeutic path where restoring miR-491-5p levels could be beneficial in countering the aggressive behavior of prostate cancer cells.

The data presented by the research team extends beyond basic biology. Their functional assays demonstrate that FOXD3-AS1 is not merely a bystander in cancer progression but a pivotal regulator of several oncogenic pathways. In various experimental setups, they documented that cells with decreased FOXD3-AS1 exhibited lower migration and invasion capabilities, aligning with the notion that lncRNAs can influence metastasis. This finding emphasizes the importance of exploring lncRNAs not just as molecular markers but as active regulators in cancer biology.

The therapeutic implications of this study are significant. Current treatments for prostate cancer, such as androgen deprivation therapy and chemotherapy, often encounter resistance, making novel targets essential for improving patient outcomes. The study’s findings propose that targeting FOXD3-AS1 could sensitize cancer cells to existing therapies or serve as a standalone treatment option, thereby providing new hope in the battle against prostate cancer.

Furthermore, the research underscores the necessity of developing drug delivery systems that can effectively target lncRNAs like FOXD3-AS1. Advances in nanotechnology and molecular biology offer promising avenues for creating therapies that can selectively silence harmful lncRNAs while minimizing off-target effects. A tailored approach that considers the patient’s unique genetic makeup will be crucial in the era of precision medicine.

As investigations continue, the potential of combining lncRNA silencing with other therapeutic strategies appears promising. Integrating FOXD3-AS1 knockdown with immunotherapy or newer targeted therapies could forge pathways to improved survival rates and quality of life for patients battling prostate cancer. This multifaceted approach aligns with the evolving understanding that cancer is not just a single disease but rather an amalgamation of distinct yet interconnected pathways.

In conclusion, the research conducted by Yu, Liu, and Wen opens an exciting new chapter in prostate cancer research. By focusing on the role of the lncRNA FOXD3-AS1, the study not only elucidates its function in the progression of prostate cancer but also heralds the potential for innovative therapies that could one day transform patient management. This work exemplifies the critical need to explore the intricate networks that govern cancer biology, paving the way for breakthroughs that could significantly enhance the lives of those affected by this disease.

As the scientific community continues to unveil the mysteries surrounding non-coding RNAs and their implications in cancer, it is evident that further research is essential to realize the clinical potential of these molecular players. The journey from bench to bedside is fraught with challenges, but the promise that lncRNAs such as FOXD3-AS1 hold cannot be overstated. The hope is that by continuing to unravel these complex interactions, we may soon see a paradigm shift in how we understand and treat prostate cancer in years to come.

Subject of Research: The role of FOXD3-AS1 in prostate cancer progression through interaction with miR-491-5p and PEG10.

Article Title: Knockdown of FOXD3-AS1 inhibits the progression of prostate cancer by targeting miR-491-5p/PEG10.

Article References: Yu, Y., Liu, Q. & Wen, Y. Knockdown of FOXD3-AS1 inhibits the progression of prostate cancer by targeting miR-491-5p/PEG10. J Cancer Res Clin Oncol 151, 329 (2025). https://doi.org/10.1007/s00432-025-06364-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06364-x

Keywords: FOXD3-AS1, prostate cancer, miR-491-5p, PEG10, lncRNA, cancer therapy.